The quest to overcome resistance to EGFR-targeted therapies in cancer

被引：957

作者：

Chong, Curtis R. ^{[1
,2
]}

Jaenne, Pasi A. ^{[1
,2
,3
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA

来源：

NATURE MEDICINE | 2013年 / 19卷 / 11期

基金：

美国国家卫生研究院;

关键词：

EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; FACTOR-RECEPTOR GENE; EPITHELIAL-MESENCHYMAL-TRANSITION; METASTATIC COLORECTAL-CANCER; CETUXIMAB PLUS IRINOTECAN; K-RAS MUTATIONS; ACQUIRED-RESISTANCE;

D O I：

10.1038/nm.3388

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance. An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors. Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors. We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.

引用

页码：1389 / 1400

页数：12

共 192 条

[1]

Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung [J].

Alam, Naheed ;

Gustafson, Karen S. ;

Ladanyi, Marc ;

Zakowski, Maureen F. ;

Kapoor, Atul ;

Truskinovsky, Alexander M. ;

Dudek, Arkadiusz Z. .

CLINICAL LUNG CANCER, 2010, 11 (05) :E1-E4

[2]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3]

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[4]

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis [J].

Ardito, Christine M. ;

Gruener, Barbara M. ;

Takeuchi, Kenneth K. ;

Lubeseder-Martellato, Clara ;

Teichmann, Nicole ;

Mazur, Pawel K. ;

DelGiorno, Kathleen E. ;

Carpenter, Eileen S. ;

Halbrook, Christopher J. ;

Hall, Jason C. ;

Pal, Debjani ;

Briel, Thomas ;

Herner, Alexander ;

Trajkovic-Arsic, Marija ;

Sipos, Bence ;

Liou, Geou-Yarh ;

Storz, Peter ;

Murray, Nicole R. ;

Threadgill, David W. ;

Sibilia, Maria ;

Washington, M. Kay ;

Wilson, Carole L. ;

Schmid, Roland M. ;

Raines, Elaine W. ;

Crawford, Howard C. ;

Siveke, Jens T. .

CANCER CELL, 2012, 22 (03) :304-317

[5]

Atagi S., 2011, 14 WORLD C LUNG CANC

[6]

PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis [J].

Bean, Gregory R. ;

Ganesan, Yogesh Tengarai ;

Dong, Yiyu ;

Takeda, Shugaku ;

Liu, Han ;

Chan, Po M. ;

Huang, Yafen ;

Chodosh, Lewis A. ;

Zambetti, Gerard P. ;

Hsieh, James J. -D. ;

Cheng, Emily H. -Y. .

SCIENCE SIGNALING, 2013, 6 (268)

[7]

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[8]

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment [J].

Becker, A. ;

Crombag, L. ;

Heideman, D. A. M. ;

Thunnissen, F. B. ;

van Wijk, A. W. ;

Postmus, P. E. ;

Smit, E. F. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) :2603-2606

[9]

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J].

Bell, DW ;

Gore, I ;

Okimoto, RA ;

Godin-Heymann, N ;

Sordella, R ;

Mulloy, R ;

Sharma, SV ;

Brannigan, BW ;

Mohapatra, G ;

Settleman, J ;

Haber, DA .

NATURE GENETICS, 2005, 37 (12) :1315-1316

[10]

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR [J].

Bivona, Trever G. ;

Hieronymus, Haley ;

Parker, Joel ;

Chang, Kenneth ;

Taron, Miquel ;

Rosell, Rafael ;

Moonsamy, Philicia ;

Dahlman, Kimberly ;

Miller, Vincent A. ;

Costa, Carlota ;

Hannon, Gregory ;

Sawyers, Charles L. .

NATURE, 2011, 471 (7339) :523-526

← 1 2 3 4 5 6 7 8 9 10 →